Ceftobiprole medocaril

Méndez, Raúl; Latorre, A; González-Jiménez, P

doi:10.37201/req/s01.05.2022

Cited by 3 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Además, no presenta actividad contra Burkholderia cepacia y Stenotrophomonas maltophilia. El ceftobiprol también presenta una actividad significativa contra gérmenes grampositivos, como, Streptococcus pneumoniae y Staphylococcus aureus resistente a la meticilina [102].…”

Section: Nuevos Antibióticosunclassified

Community-acquired pneumonia: Epidemiology, diagnosis, prognostic severity scales, and new therapeutic options

Oliveira e Silva,

Cerqueira Batista Filho,

Pérez Flores

et al. 2023

Medwave

View full text Add to dashboard Cite

This narrative review article explores the current scientific knowledge on the definition, epidemiology, diagnostic criteria, microbiology, treatment, and prevention of severe community-acquired pneumonia (SCAP) in immunocompetent adults. At present, despite major scientific advances in diagnostic evaluation, clinical management, antimicrobial therapy, and prevention, severe community-acquired pneumonia remains a major cause of morbidity and mortality, as well as having a major economic impact in terms of increased healthcare expenditure worldwide. This pathology is considered one of the leading causes of sepsis/septic shock, with an extremely high overall mortality rate, which justifies all the effort in early diagnosis, proper management, and prompt initiation of antimicrobial therapy. Including biomarkers (isolated or in combination) associated with applying diagnostic criteria and prognostic severity scales in clinical practice helps identify patients with severe community-acquired pneumonia, defines immediate admission to the intensive care unit, and, thus, minimizes the adverse outcomes of this serious pathology.

show abstract

Section: Nuevos Antibióticosunclassified

Community-acquired pneumonia: Epidemiology, diagnosis, prognostic severity scales, and new therapeutic options

Oliveira e Silva,

Cerqueira Batista Filho,

Pérez Flores

et al. 2023

Medwave

View full text Add to dashboard Cite

show abstract

New antibiotics for Gram-negative pneumonia

et al. 2022

View full text Add to dashboard Cite

Pneumonia is frequently encountered in clinical practice, and Gram-negative bacilli constitute a significant proportion of its aetiology, especially when it is acquired in a hospital setting. With the alarming global rise in multidrug resistance in Gram-negative bacilli, antibiotic therapy for treating patients with pneumonia is challenging and must be guided byin vitrosusceptibility results. In this review, we provide an overview of antibiotics newly approved for the treatment of pneumonia caused by Gram-negative bacilli. Ceftazidime-avibactam, imipenem-relebactam and meropenem-vaborbactam have potent activity against some of the carbapenem-resistant Enterobacterales, especiallyKlebsiella pneumoniaecarbapenemase producers. Several novel antibiotics have potent activity against multidrug-resistantPseudomonas aeruginosa, such as ceftazidime-avibactam, ceftolozane-tazobactam, imipenem-relabactam and cefiderocol. Cefiderocol may also play an important role in the management of pneumonia caused byAcinetobacter baumannii, along with plazomicin and eravacycline.

show abstract

Agents Targeting the Bacterial Cell Wall as Tools to Combat Gram-Positive Pathogens

Zhydzetski,

Głowacka-Grzyb,

Bukowski

et al. 2024

Molecules

View full text Add to dashboard Cite

The cell wall is an indispensable element of bacterial cells and a long-known target of many antibiotics. Penicillin, the first discovered beta-lactam antibiotic inhibiting the synthesis of cell walls, was successfully used to cure many bacterial infections. Unfortunately, pathogens eventually developed resistance to it. This started an arms race, and while novel beta-lactams, either natural or (semi)synthetic, were discovered, soon upon their application, bacteria were developing resistance. Currently, we are facing the threat of losing the race since more and more multidrug-resistant (MDR) pathogens are emerging. Therefore, there is an urgent need for developing novel approaches to combat MDR bacteria. The cell wall is a reasonable candidate for a target as it differentiates not only bacterial and human cells but also has a specific composition unique to various groups of bacteria. This ensures the safety and specificity of novel antibacterial agents that target this structure. Due to the shortage of low-molecular-weight candidates for novel antibiotics, attention was focused on peptides and proteins that possess antibacterial activity. Here, we describe proteinaceous agents of various origins that target bacterial cell wall, including bacteriocins and phage and bacterial lysins, as alternatives to classic antibiotic candidates for antimicrobial drugs. Moreover, advancements in protein chemistry and engineering currently allow for the production of stable, specific, and effective drugs. Finally, we introduce the concept of selective targeting of dangerous pathogens, exemplified by staphylococci, by agents specifically disrupting their cell walls.

show abstract

Ceftobiprole medocaril

Cited by 3 publications

References 7 publications

Community-acquired pneumonia: Epidemiology, diagnosis, prognostic severity scales, and new therapeutic options

Community-acquired pneumonia: Epidemiology, diagnosis, prognostic severity scales, and new therapeutic options

New antibiotics for Gram-negative pneumonia

Agents Targeting the Bacterial Cell Wall as Tools to Combat Gram-Positive Pathogens

Contact Info

Product

Resources

About